Los Angeles Capital Management LLC Has $1.84 Million Stock Holdings in Progyny, Inc. (NASDAQ:PGNY)

Los Angeles Capital Management LLC trimmed its position in Progyny, Inc. (NASDAQ:PGNY) by 2.7% in the fourth quarter, Holdings Channel.com reports. The firm owned 49,419 shares of the company’s stock after selling 1,361 shares during the period. Los Angeles Capital Management LLC’s holdings in Progyny were worth $1,837,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its holdings in Progyny by 7.4% during the 3rd quarter. Vanguard Group Inc. now owns 8,157,604 shares of the company’s stock worth $277,522,000 after acquiring an additional 565,160 shares during the period. International Assets Investment Management LLC grew its stake in shares of Progyny by 352,414.2% during the fourth quarter. International Assets Investment Management LLC now owns 5,876,411 shares of the company’s stock worth $218,485,000 after purchasing an additional 5,874,744 shares during the period. Jennison Associates LLC increased its holdings in Progyny by 19.4% in the third quarter. Jennison Associates LLC now owns 2,706,454 shares of the company’s stock valued at $92,074,000 after purchasing an additional 438,932 shares during the last quarter. Principal Financial Group Inc. lifted its stake in Progyny by 6.1% in the third quarter. Principal Financial Group Inc. now owns 1,230,569 shares of the company’s stock valued at $41,864,000 after buying an additional 70,449 shares during the period. Finally, Northern Trust Corp boosted its holdings in Progyny by 1.3% during the third quarter. Northern Trust Corp now owns 1,166,806 shares of the company’s stock worth $39,695,000 after buying an additional 15,208 shares during the last quarter. 94.93% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts have recently commented on PGNY shares. KeyCorp lowered their price target on Progyny from $45.00 to $43.00 and set an “overweight” rating for the company in a research note on Wednesday, February 28th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $48.00 target price on shares of Progyny in a report on Wednesday, February 28th. Truist Financial restated a “buy” rating and issued a $46.00 price objective on shares of Progyny in a research report on Wednesday, April 17th. Leerink Partnrs reiterated an “outperform” rating on shares of Progyny in a report on Monday, February 26th. Finally, SVB Leerink initiated coverage on shares of Progyny in a research report on Monday, February 26th. They set an “outperform” rating and a $49.00 price objective for the company. Ten investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $48.30.

Progyny Price Performance

Progyny stock opened at $33.06 on Wednesday. The company has a market cap of $3.18 billion, a price-to-earnings ratio of 53.32, a P/E/G ratio of 1.31 and a beta of 1.51. The firm has a 50-day moving average of $34.80 and a 200-day moving average of $35.63. Progyny, Inc. has a one year low of $29.44 and a one year high of $44.95.

Progyny (NASDAQ:PGNY) last issued its quarterly earnings results on Tuesday, February 27th. The company reported $0.13 EPS for the quarter, beating the consensus estimate of $0.09 by $0.04. The firm had revenue of $269.94 million during the quarter, compared to analysts’ expectations of $274.08 million. Progyny had a return on equity of 12.64% and a net margin of 5.70%. The business’s quarterly revenue was up 26.0% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.03 earnings per share. As a group, sell-side analysts expect that Progyny, Inc. will post 0.7 earnings per share for the current year.

Insider Activity at Progyny

In other Progyny news, Chairman David J. Schlanger sold 71,272 shares of the company’s stock in a transaction on Wednesday, March 27th. The shares were sold at an average price of $37.80, for a total transaction of $2,694,081.60. Following the sale, the chairman now directly owns 86,312 shares of the company’s stock, valued at $3,262,593.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, Chairman David J. Schlanger sold 71,272 shares of the business’s stock in a transaction that occurred on Wednesday, March 27th. The stock was sold at an average price of $37.80, for a total transaction of $2,694,081.60. Following the transaction, the chairman now directly owns 86,312 shares of the company’s stock, valued at approximately $3,262,593.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Chairman David J. Schlanger sold 1,000 shares of the firm’s stock in a transaction on Monday, April 1st. The shares were sold at an average price of $37.52, for a total value of $37,520.00. Following the sale, the chairman now directly owns 83,631 shares of the company’s stock, valued at approximately $3,137,835.12. The disclosure for this sale can be found here. Over the last three months, insiders sold 102,770 shares of company stock valued at $3,853,985. 12.30% of the stock is owned by corporate insiders.

About Progyny

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.